Study guide
Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis
AANPCB Adult-Gerontology Primary Care Nurse Practitioner A-GNP
Track your progress as you read
Finished sections get a check mark.
1 Exam Structure, APRN Foundations & Geriatric Assessment
A-GNP Exam Logistics, Blueprint & Scoring Structure APRN Scope of Practice, Consensus Model & Interprofessional Collaboration Comprehensive Health History & Subjective Assessment Across Adult Lifespan Comprehensive Physical Examination & Clinical Assessment Skills
2 Health Assessment, Diagnostic Reasoning & Clinical Procedures
Diagnostic Reasoning, Test Interpretation & Clinical Decision-Making Screening Guidelines & Evidence-Based Health Promotion (USPSTF) Comprehensive Geriatric Assessment (CGA), Frailty & Function In-Office Clinical Procedures, ECG Interpretation & Minor Surgical Skills
3 Cardiovascular & Peripheral Vascular Disorders
Essential Hypertension & Hypertensive Urgency/Emergency Management Coronary Artery Disease, Acute Coronary Syndromes & Post-MI Care Heart Failure (HFrEF & HFpEF) Diagnosis, Staging & 4-Pillar GDMT Arrhythmias (Atrial Fibrillation), Valvular Heart Disease & PAD
4 Respiratory, HEENT & Dermatological Disorders
Asthma Management across the Adult Lifespan (GINA Guidelines) Chronic Obstructive Pulmonary Disease (COPD) Staging & Management (GOLD Guidelines) Community-Acquired Pneumonia & Lower Respiratory Tract Infections Common HEENT Disorders: Otitis, Sinusitis, Pharyngitis, Glaucoma & Macular Degeneration
5 Endocrine, Metabolic & Renal/Genitourinary Disorders
Type 2 Diabetes Mellitus Management Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Subclinical Disease Chronic Kidney Disease (CKD) Staging & Diabetic/Hypertensive Nephropathy Genitourinary Disorders: BPH, Urinary Incontinence, UTIs & Prostatitis
6 Gastrointestinal, Hematologic & Immunologic Disorders
Upper Gastrointestinal Disorders: Dyspepsia, GERD, PUD & H. pylori Lower Gastrointestinal Disorders: IBS, IBD, Diverticulitis & Colorectal Screening Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis Hematologic & Immunologic Disorders: Anemias, Anticoagulation & Immunizations
7 Neurological, Cognitive & Psychiatric Disorders
Cognitive Assessment: Delirium, Dementia & Mild Cognitive Impairment Neurological Disorders: Stroke, TIA, Parkinson's Disease & Headache Syndromes Major Depressive Disorder & Anxiety Disorders in Adults & Older Adults Sleep Disorders, Insomnia & Restless Legs Syndrome
8 Geriatric Syndromes, Polypharmacy & Deprescribing
The Beers Criteria & STOPP/START Criteria for Potentially Inappropriate Medication Use Polypharmacy Management, Pharmacokinetics/Pharmacodynamics in Aging & Deprescribing Protocols Fall Risk Assessment (CDC STEADI), Gait/Balance & Mobility Impairments Pressure Injury Prevention/Staging, Urinary/Fecal Incontinence & Frailty Assessment
9 APRN Professional Practice, Ethics, Quality & Healthcare Policy
Musculoskeletal Disorders: Osteoarthritis, Osteoporosis, Gout & Back Pain Dermatological Disorders: Lesions, Skin Cancers, Infections & Rash Evaluation Palliative Care, Advance Care Planning, Pain Management & End-of-Life APRN Professional Practice, Quality Improvement, Ethics & Healthcare Policy
Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis
Key Takeaways Explain This Topic AI
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD, formerly NAFLD) is characterized by hepatic steatosis linked with metabolic risk factors; ALT is typically higher than AST (AST/ALT ratio < 1) in uncomplicated disease.
Non-invasive risk stratification for liver fibrosis in MASLD utilizes the FIB-4 index (age, AST, ALT, platelets); a score < 1.30 has a high negative predictive value for advanced fibrosis.
Serum-Ascites Albumin Gradient (SAAG) >= 1.1 g/dL confirms portal hypertension as the etiology of ascites; Spontaneous Bacterial Peritonitis (SBP) is diagnosed by an ascitic absolute neutrophil count (ANC) >= 250 cells/mm³.
Acute cholecystitis presents with steady RUQ pain, fever, leukocytosis, and a positive Murphy's sign; ultrasound findings include gallbladder wall thickening (>3-4 mm), pericholecystic fluid, and sonographic Murphy sign.
Acute pancreatitis diagnosis requires at least 2 of 3 criteria: classic severe epigastric pain radiating to the back, serum lipase or amylase >= 3 times upper limit of normal, and characteristic cross-sectional imaging.
Last updated: July 2026
- Liver, Biliary & Pancreatic Disorders: NAFLD/MASLD, Cirrhosis & Cholecystitis
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD / NAFLD)
Under AASLD consensus guidelines, Nonalcoholic Fatty Liver Disease (NAFLD) is termed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) . MASLD defines hepatic steatosis occurring with at least one cardiometabolic risk factor (central obesity, type 2 diabetes, hypertension, hypertriglyceridemia, low HDL) without heavy alcohol intake (<20 g/day women, <30 g/day men). Insulin resistance drives increased hepatic de novo lipogenesis and impaired fatty acid beta-oxidation.
MASH (Metabolic Dysfunction-Associated Steatohepatitis) : The progressive inflammatory subtype characterized by hepatic steatosis, lobular inflammation, and hepatocellular ballooning degeneration. MASH drives progressive liver fibrosis, cirrhosis, and Hepatocellular Carcinoma (HCC) .
Diagnostics & FIB-4 Risk Stratification
Patients are usually asymptomatic, presenting with incidental aminotransferase elevations ( ALT > AST , AST/ALT ratio < 1 in early disease, distinguishing it from alcoholic liver disease where AST/ALT > 2). Abdominal ultrasound shows increased hepatic echogenicity ("bright liver").
Fibrosis risk stratification in primary care:
FIB-4 Index (incorporating Age, AST, ALT, and Platelet Count): FIB-4 = Age (years) × AST (U/L) Platelets ( 10 9 / L ) × ALT (U/L) \text{FIB-4} = \frac{\text{Age (years)} \times \text{AST (U/L)}}{\text{Platelets } (10^9/\text{L}) \times \sqrt{\text{ALT (U/L)}}} FIB-4 = Platelets ( 1 0 9 / L ) × ALT (U/L) Age (years) × AST (U/L)
FIB-4 < 1.30 (<2.0 in age >=65): Low risk for advanced fibrosis; managed in primary care with lifestyle modification.
FIB-4 1.30 to 2.67 : Indeterminate risk; secondary testing with Transient Elastography (FibroScan) required.
FIB-4 > 2.67 : High risk for advanced fibrosis; urgent Hepatology referral.
Liver Biopsy : Definitive gold standard to stage fibrosis.
Management Protocols
Weight Loss : 7% to 10% total body weight loss resolves MASH and regresses fibrosis.
Pharmacotherapy : GLP-1 receptor agonists (semaglutide, tirzepatide) improve glycemic control, promote weight loss, reduce steatosis, and prevent fibrosis progression; Resmetirom (selective thyroid hormone receptor-beta agonist dosing 80 mg or 100 mg daily based on body weight) for non-cirrhotic MASH with moderate-to-advanced fibrosis (stages F2-F3).
Statin Safety : Statins are safe and explicitly indicated in MASLD/MASH to lower cardiovascular disease mortality, the leading cause of death in this population.
Cirrhosis & Complications of End-Stage Liver Disease
Cirrhosis is irreversible end-stage liver disease characterized by diffuse hepatic fibrosis, disruption of lobular architecture, and regenerative nodules.
Physical Exam Stigmata & Major Complications
Physical stigmata include spider angiomas, palmar erythema, gynecomastia, caput medusae, Dupuytren contracture, jaundice, scleral icterus, splenomegaly, and asterixis (flapping tremor).
1. Portal Hypertension & Esophageal Varices
Elevated portal vascular resistance causes collateral venous dilation.
Screening EGD required for all cirrhotic patients.
Primary prophylaxis for medium/large varices: Non-selective beta-blockers ( nadolol , propranolol , carvedilol ) or endoscopic variceal band ligation (EVL).
2. Ascites & Spontaneous Bacterial Peritonitis (SBP)
SAAG Calculation : Serum Albumin − Ascitic Albumin \text{Serum Albumin} - \text{Ascitic Albumin} Serum Albumin − Ascitic Albumin .
SAAG >= 1.1 g/dL : Confirms Portal Hypertension (cirrhosis, heart failure).
SAAG < 1.1 g/dL : Non-portal hypertension etiologies (peritoneal carcinomatosis, tuberculosis).
Ascites Management : Sodium restriction (<2000 mg/day) + oral diuretics: Spironolactone and Furosemide at a 100 mg : 40 mg ratio (up to max 400 mg : 160 mg daily).
Spontaneous Bacterial Peritonitis (SBP) : Bacterial translocation from gut lumen into ascites without intra-abdominal surgical infection.
Diagnostic Benchmark : Ascitic fluid Absolute Neutrophil Count (ANC) >= 250 cells/mm³ (WBC x % neutrophils).
Treatment : IV 3rd gen cephalosporin ( cefotaxime or ceftriaxone ) + IV Albumin (1.5 g/kg day 1, 1 g/kg day 3).
Prophylaxis : Long-term oral fluoroquinolone (ciprofloxacin) or TMP-SMX.
3. Hepatic Encephalopathy
Driven by systemic ammonia accumulation, precipitated by infection, constipation, hyponatremia, or GI bleeding.
First-Line : Lactulose titrated to 2 to 3 soft bowel movements daily (converts N H 3 NH_3 N H 3 to non-absorbable N H 4 + NH_4^+ N H 4 + ).
Add-on Therapy : Oral Rifaximin (550 mg BID).
4. HCC Surveillance
Abdominal ultrasound +/- serum alpha-fetoprotein (AFP) every 6 months .
Viral Hepatitis Overview & Screening
Hepatitis B : Screen with HBsAg, Anti-HBs, Anti-HBc. Universal screening recommended for all adults at least once per lifetime.
Hepatitis C : USPSTF mandates universal one-time screening for all adults aged 18 to 79 (HCV antibody with reflex RNA PCR). Curable with oral direct-acting antiviral (DAA) therapy for 8-12 weeks.
Biliary & Pancreatic Disorders
Biliary Colic : Episodic postprandial RUQ pain lasting <6 hours due to transient cystic duct obstruction; normal labs.
Acute Cholecystitis : Prolonged cystic duct obstruction causing constant RUQ pain (>6 hours), fever, leukocytosis, and Murphy's Sign (inspiratory arrest during subcostal palpation).
Ultrasound Findings : Gallbladder wall thickening (>3-4 mm), pericholecystic fluid, gallstones, and sonographic Murphy sign. A HIDA scan (hepatobiliary iminodiacetic acid scan demonstrating non-visualization of the gallbladder) is indicated if ultrasound is equivocal.
Treatment : NPO, IV isotonic fluids, IV broad-spectrum antibiotics, and early laparoscopic cholecystectomy (within 24-72 hours of admission).
Choledocholithiasis & Cholangitis : Common bile duct stone causing jaundice and elevated direct bilirubin/alk phos. Ascending cholangitis presents with Charcot's Triad (RUQ pain, fever, jaundice) or Reynolds' Pentad (+ hypotension/altered mental status), requiring emergency ERCP for biliary decompression.
Acute Pancreatitis : Caused by gallstones (40%) or alcohol (30%), followed by hypertriglyceridemia (>1000 mg/dL). Severe epigastric pain radiating to back, relieved leaning forward. Exam may show Cullen's or Grey Turner's sign in hemorrhagic cases.
Atlanta Diagnostic Criteria (requires >= 2 of 3): 1) Classic epigastric pain, 2) Serum Lipase >= 3 times upper limit of normal , 3) Characteristic CT/MRI imaging.
Management : Aggressive IV hydration with Lactated Ringer's solution (200-500 mL/hr), early oral refeeding as tolerated. Clinical severity is evaluated using Ranson criteria or BISAP score.